Study confirms link between glucose tolerance, dementia New diabetes research chair at SherbrookeThe Université de Sherbrooke has created a research chair on the causes of type 2 diabetes. It will focus on preventive measures and early treatment for this chronic disease. The prime target, says the university, is how a high-fat diet triggers the disease. Ottawa to host conference on womens’ mental health The Royal Ottawa Mental Health Centre will hold one of Canada’s first conferences on women’s mental health. Trajenta: third DDP-4 inhibitor for type 2 diabetes Drug indicated for improving glycemic control in adults with type 2 diabetes. Practice Issues: Calcium intake and fracture risk Study investigates associations between long-term dietary intake of calcium and risk of fracture. Practice Issues: Exemestane for breast cancer chemoprevention Is exemestane a good option for breast cancer chemoprevention in postmenopausal women? Drug News: October 2011 Edurant: new NNRTI for HIV; Trajenta: third DDP-4 inhibitor for type 2 diabetes; Victrelis for chronic hepatitis C. Weight gain fears from combining insulin and liraglutide quelled Concerns that the addition of insulin to type 2 diabetes patients already on the new injectable glucagon-like peptide (GLP-1) liraglutide could result in weight gain may not be warranted, researchers suggested here. New antiretroviral agent added to HIV arsenal Investigational diabetes drug from controversial class shows promise But Japanese patient population that was the subject of this study has different risk factors compared with other groups First Previous 169 170 171 172 173 Next Last
